- Home
- KURA vs CSTL Comparison
KURA vs CSTL Comparison
Compare KURA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- CSTL
- Stock Information
- Founded
- KURA 2014
- CSTL 2007
- Country
- KURA United States
- CSTL United States
- Employees
- KURA N/A
- CSTL N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- CSTL Medical Specialities
- Sector
- KURA Health Care
- CSTL Health Care
- Exchange
- KURA Nasdaq
- CSTL Nasdaq
- Market Cap
- KURA 561.9M
- CSTL 561.9M
- IPO Year
- KURA N/A
- CSTL 2019
- Fundamental
- Price
- KURA $6.47
- CSTL $16.43
- Analyst Decision
- KURA Strong Buy
- CSTL Strong Buy
- Analyst Count
- KURA 12
- CSTL 6
- Target Price
- KURA $24.50
- CSTL $37.67
- AVG Volume (30 Days)
- KURA 1.4M
- CSTL 425.9K
- Earning Date
- KURA 08-07-2025
- CSTL 08-04-2025
- Dividend Yield
- KURA N/A
- CSTL N/A
- EPS Growth
- KURA N/A
- CSTL N/A
- EPS
- KURA N/A
- CSTL N/A
- Revenue
- KURA $67,991,000.00
- CSTL $347,083,000.00
- Revenue This Year
- KURA $125.04
- CSTL N/A
- Revenue Next Year
- KURA $83.75
- CSTL $1.36
- P/E Ratio
- KURA N/A
- CSTL N/A
- Revenue Growth
- KURA N/A
- CSTL 38.43
- 52 Week Low
- KURA $5.41
- CSTL $15.45
- 52 Week High
- KURA $21.60
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- KURA 55.28
- CSTL 33.31
- Support Level
- KURA $6.26
- CSTL $16.16
- Resistance Level
- KURA $6.74
- CSTL $17.31
- Average True Range (ATR)
- KURA 0.31
- CSTL 0.82
- MACD
- KURA 0.05
- CSTL -0.41
- Stochastic Oscillator
- KURA 75.25
- CSTL 6.50
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.